Results 81 to 90 of about 4,832 (178)

Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study

, 2023
Background and Aim: Benralizumab is a biologic add-on treatment for severe eosinophilic asthma that can reduce the rate of asthma exacerbations, but data on the associated medical utilization are scarce.
Donna Carstens (16542582), Yen Chung (16542576), Danni Yang (1403032), Fan Mu (5783894), Joshua A. Young (4251787), Eduardo Genofre (16542579), Erin E. Cook (9467231), Keith A. Betts (4169101), Diego J. Maselli (14635129)   +8 more
core   +1 more source

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy

, 2018
Corrado Pelaia,1 Alessandro Vatrella,2 Andrea Bruni,1 Rosa Terracciano,3 Girolamo Pelaia1 1Department of Medical and Surgical Sciences, Section of Respiratory Diseases, “Magna Græcia” University of Catanzaro, Catanzaro, Italy ...
Vatrella A, Pelaia C, Terracciano R, Bruni A, Pelaia G   +4 more
core  

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

International audienceBACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an
Jison, Maria, Wechsler, Michael M.E., Jayne, David, Jackson, David J., Shavit, Anat, Walz, Bastian, Wechsler, Michael E., Merkel, Peter PA, Jackson, David J, Mccrae, Christopher, Jackson, David, Nair, Parameswaran, Börjesson Sjö, Lena, Jayne, David R.W., Jayne, David R.W.David, Fan, Ying, Wechsler, Michael, Roufosse, Florence, Merkel, Peter, Merkel, Peter A., Walton, Claire, Bourdin, Arnaud, Sjö, Lena Börjesson, Necander, Sofia, Fan, Yingying, Terrier, Benjamin   +25 more
core   +1 more source

Benralizumab in Real Life [PDF]

Journal of Investigational Allergology and Clinical Immunology, 2021
J C, Miralles López, A I, Escudero Pastor, A, Carbonell Martínez, C, Navarro Garrido, Y, Bonilla Pacheco, Y, Petrik Petrik   +5 more
openaire   +2 more sources

Effectiveness of benralizumab in the Tokyo Asthma Study (TOAST): A real-world prospective interventional trial

Allergology International
Background: Biologics are integral in the management of severe asthma. As the effectiveness of the anti-IL-5 receptor antibody benralizumab in Japan remains elusive, this study aimed to assess its real-world effectiveness in Japanese patients with severe
Katsunori Masaki, Maho Suzukawa, Hitoshi Sasano, Norihiro Harada, Yasunari Miyazaki, Hideki Katsura, Etsuko Tagaya, Junko Terada, Masayuki Hojo, Naoya Sugimoto, Hiroyuki Nagase, Yuta Kono, Hisato Hiranuma, Yasuhiro Gon, Ryo Takemura, Misato Irie, Reina Nakamura, Hiroki Kabata, Jun Miyata, Koichi Fukunaga   +19 more
doaj   +1 more source

Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma

Journal of Asthma and Allergy, 2019
J Mark FitzGerald,1 Eugene R Bleecker,2 Arnaud Bourdin,3 William W Busse,4 Gary T Ferguson,5 Laura Brooks,6 Peter Barker,6 Ubaldo J Martin6 1Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung ...
FitzGerald JM, Bleecker ER, Bourdin A, Busse WW, Ferguson GT, Brooks L, Barker P, Martin UJ   +7 more
doaj  

Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study

Frontiers in Allergy
IntroductionSevere eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients ...
Luisa Brussino, Maria Aliani, Elena Altieri, Pietro Bracciale, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Giorgio Walter Canonica, Cristiano Caruso, Cristiano Caruso, Stefano Centanni, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Laura Malerba, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Gianenrico Senna, Alessandra Vultaggio, Maria D’Amato   +24 more
doaj   +1 more source

Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction

Yair Humberto González-Tuyub,1 Karla Daniela González-Iñiguez,1 Paula Catalina Lizarazo-Guiza,2 Sergio Ricardo García-García3 1Clinical Immunology and Allergy Service, ISSSTE Hospital Regional General, Ignacio Zaragoza, Ciudad de México, México; 2Medical
González-Tuyub YH, Lizarazo-Guiza PC, García-García SR, González-Iñiguez KD   +3 more
core  

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic

Biologics: Targets & Therapy, 2019
Marco Caminati,1,2 Diego Bagnasco,3 Rachele Vaia,2 Gianenrico Senna11Asthma Center and Allergy Unit, Verona University Hospital, Verona, Italy; 2Department of Medicine, School of Specialization in Allergy and Clinical Immunology, University of Verona ...
Caminati M, Bagnasco D, Vaia R, Senna G
doaj  

Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab

ACR Open Rheumatology
Objective In the phase 3 head‐to‐head MANDARA study (NCT04157348), benralizumab demonstrated noninferiority to mepolizumab in inducing remission (defined as Birmingham Vasculitis Activity Score [BVAS] of 0 and oral glucocorticoid [OGC] dosage ≤4 mg/day ...
Michael E. Wechsler, Nancy Agmon‐Levin, David R. W. Jayne, Christian Pagnoux, Ulrich Specks, Lena Börjesson Sjö, Sofia Necander, Anat Shavit, Claire Walton, Peter A. Merkel   +9 more
doaj   +1 more source